On September 22, Natera announced that Signatera had received approval in Japan as a companion diagnostic for postoperative treatment of muscle-invasive bladder cancer. The test uses information from a patient's tumor to track cancer-derived DNA in the blood and inform decisions about additional treatment. Company announcement ↗
Whereas histopathology examines the appearance of tissues and cells, Signatera looks for DNA variants identified in a patient's tumor in blood collected after surgery. It is designed to detect molecular traces of residual cancer, even before lesions become visible on imaging. FDA device information ↗
In the trial supporting this use, patients who tested positive after surgery had longer disease-free and overall survival with atezolizumab than with placebo. Clinical trial ↗
The test discussed in “Can Shield Bring More People into Colorectal Cancer Screening?” ↗ was intended to direct people with suspected cancer toward further diagnostic investigation. This use concerns additional treatment for patients who have already undergone surgery. It brings blood testing and drug treatment together, using evidence of residual disease to inform the next treatment decision.
Evidence & reading
Public sources checked for this edition. Linked pages may subsequently change.
- 企業発表 ↗www.natera.com · recorded 2026-09-29
- FDAの検査情報 ↗www.accessdata.fda.gov · recorded 2026-09-29
- 臨床試験 ↗pubmed.ncbi.nlm.nih.gov · recorded 2026-09-29
READER DISCUSSION
What does this change for you?
A question, a different reading, or a source we should consider. A short comment is welcome.
Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules
Loading discussion…
Also in this issue
Contents →R&D Allocation
Transporting Cell Therapies Without Refrigeration
ARPA-H's BoSS program is funding preservation materials and processes intended to let therapeutic cells withstand room-temperature storage.
Frontier Science
Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
Research on autoimmune psychiatric symptoms is informing treatments designed to protect receptors from pathogenic antibodies.
Commercialization
After AI Finds a Candidate, What Gets Paid For?
Experimental services and ownership of drug discovery assets offer different ways to earn revenue after AI identifies a candidate.
Commercialization
What Does Chugai Still See in a Drug Roche Is Walking Away From?
GYM329's planned return to SMA development may be a bid to build a different product proposition—not a reversal of the evidence on efficacy.